EGFR
33 programs · 33 companies
Programs
33
Companies
33
Active Trials
24
Targeting EGFR
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| AZN-6870 | AstraZeneca | Phase 2/3 | NSCLC | |
| TAK-1836 | Takeda | Preclinical | Prostate CaMCL | |
| Zanurapivir | Neurocrine | NDA/BLA | LGS | |
| RCU-2903 | Arcus Bio | NDA/BLA | Endometrial CaRA | |
| Capicilimab | Structure Ther | Phase 1 | DMDMigraine | |
| Adagraderotide | Olema | Phase 2 | Bladder CaCF | |
| Teratenlimab | Alligator Bio | Approved | MCLPNH | |
| SAM-IIT-954 | Samsung Medical Ctr | Phase 1/2 | Dravet | |
| FRE-IIT-285 | Fred Hutch Cancer Ctr | NDA/BLA | PsA | |
| Lisorasimod | GenEdit | Phase 2/3 | Fabry | |
| Gelitenlimab | OncXerna | Preclinical | CFMCL | |
| Olpasacituzumab | Prelude | Phase 3 | RBBladder Ca | |
| Doxarapivir | Morphic Ther (Lilly) | Phase 2 | CTCLOCD | |
| Mirimavacamten | Cellectar Bio | Approved | Angelman | |
| Lisozanubrutinib | Enochian Bio | Approved | FSGSCholangiocarcinoma | |
| Semalemzoparlimab | Principia (Sanofi) | Phase 3 | Huntington's | |
| Nirasacituzumab | Sino Biopharma | Phase 3 | SMAMelanoma | |
| TRE-2745 | Treeline | Phase 2/3 | PAH | |
| Zorizumab | BioHaven (Pfizer) | Phase 1/2 | MGGA | |
| FRE-IIT-984 | Fred Hutch | Approved | Breast Ca | |
| Mavutenlimab | Achilles (BMS) | Phase 2 | MelanomaPompe | |
| BOE-3317 | Boehringer | Phase 1/2 | UCPNH | |
| Pexatinib | Bellus Health (GSK) | Phase 3 | MigraineOvarian Ca | |
| MYG-309 | Myriad Genetics | NDA/BLA | NBMM | |
| TOL-8761 | Tolmar | Phase 2 | RBAS | |
| Doxazasiran | Orion Pharma | Phase 1 | Breast Ca | |
| ESC-2972 | Esco Lifesciences | Phase 2 | Wilms | |
| Elrasacituzumab | IPCA Labs | Phase 2/3 | FabryOvarian Ca | |
| NAT-IIT-130 | Natl Cancer Ctr Singapore | Phase 1/2 | Fabry | |
| 300-6800 | Walvax Biotech | Phase 1/2 | IPF | |
| Talazanubrutinib | Sorriso Pharma | Phase 1/2 | Wet AMDFSGS | |
| Olpazumab | Avantor | Phase 1/2 | MCLNSCLC | |
| DER-8696 | Dermavant Sciences | Phase 1/2 | Gastric CaNSCLC |